


CLAIMS

1-35. (canceled)

36. (Previously Presented) A compound of formula I



each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen;

R¹ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen;

R³ is C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, or unsubstituted or substituted carbamoyl;

R⁴ is hydrogen;

R⁵ is chloro or bromo;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R^8 is C_5 - C_{10} aryl; unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S; C_5 - C_{10} aryloxy; unsubstituted or substituted heterocyclyloxy; or unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy; and R^{10} is C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, C_1 - C_8 alkoxy, unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, or halogen; and A is C; or salts thereof.

37. (Previously Presented) The compound of claim 36, wherein each of R^0 , R^1 or R^2 is hydrogen.

38. (Previously Presented) The compound of claim 36, wherein R^3 is C_1 - C_8 alkylsulfonyl, C_5 - C_{10} arylsulfonyl or unsubstituted or substituted carbamoyl.

39. (Previously Presented) The compound of claim 36, wherein R^3 is C_1 - C_8 alkylsulfonyl.

40. (Previously Presented) The compound of claim 36, wherein R^3 is C_5 - C_{10} arylsulfonyl.

41. (Previously Presented) The compound of claim 36, wherein R^3 is unsubstituted or substituted carbamoyl.


42. (Previously Presented) The compound of claim 36, wherein R^8 is piperidino, piperazino, N-methylpiperazino, morpholino, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy or 3-(N-methylpiperazino)-propoxy.

43. (Previously Presented) The compound of claim 36, wherein R^8 is unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S.

44. (Previously Presented) The compound of claim 36, wherein R^0 , R^1 or R^2 is hydrogen; R^3 is C_1 - C_8 alkylsulfonyl; and R^8 is unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S.






45. (Previously Presented) The compound of claim 44, wherein R⁸ is piperidino, piperazino, N-methylpiperazino or morpholino.






46. (Previously Presented) The compound of claim 36, wherein said compound is selected from the group of compounds with the following names or formulae: 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzamide;









a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound No.	Rx
7-1	
7-2	
7-3	


7-4	
7-5	
7-7	
7-8	
7-9	


7-10	
7-11	
7-12	
7-13	
7-14	

7-17	
7-18	
7-20	
7-21	
7-25	








a compound of the formula
given in the following table:

Compound	Rx
8-2	





a compound of the formula
given in the following table:



Compound	Rx
9-1	



9-2	
9-3	
9-4	
9-5	

9-6







a compound of the formula
given in the following table:

Compound	Rx
10-1	
10-2	









a compound of the formula $\text{F}-\text{Rx}$, wherein Rx has one of the meanings given in the following table:

Compound	Rx
11-1	
11-2	
11-4	






a compound of the formula  , wherein *Ry* has one of the meanings given in the following table:


Compound	<i>Ry</i>
14-1	
14-2	
14-3	
14-5	
14-6	



a compound of the formula given in the following table:


, wherein Rx has one of the meanings

Compound	Rx
15-1	
15-2	
15-3	










a compound of the formula $\text{O} \text{---} \text{Rx}$, wherein Rx has one of the meanings given in the following table:





Compound	Rx
18-1	 ;












a compound of the formula  , wherein Rx has one of the meanings given in the following table:





Compound	Rx
26-1	
26-2	


26-3	 Chemical structure 26-3 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group. The phenyl ring has a methoxy group (-OCH ₃) at the para position.
26-4	 Chemical structure 26-4 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group. The phenyl ring has a methoxy group (-OCH ₃) at the para position and a hydroxyl group (-OH) at the 1-position.
26-5	 Chemical structure 26-5 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group. The phenyl ring has a methoxy group (-OCH ₃) at the para position and a carbamoyl group (-CONH ₂) at the 1-position.
26-6	 Chemical structure 26-6 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group. The phenyl ring has a methoxy group (-OCH ₃) at the para position and a carbonylmethylamino group (-CONHCH ₃) at the 1-position.
26-7	 Chemical structure 26-7 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group. The phenyl ring has a methoxy group (-OCH ₃) at the para position and a dimethylaminocarbonyl group (-N(CH ₃) ₂ CONH ₂) at the 1-position.

26-8	
26-9	
26-10	
26-11	

26-12	
26-13	
26-14	
26-18	


26-21	
26-22	
26-23	
26-24	
26-25	




26-26	
26-27	
26-28	
26-29	




a compound of the formula
given in the following table:






Compound	Rx
----------	----











27-6	
27-8	
27-9	 ;




a compound of the formula
given in the following table:
 , wherein Rx has one of the meanings


Compound	Rx
28-1	
28-2	
28-3	
28-4	
28-5	


28-6	
28-8	
28-9	
28-10	

28-11	
28-12	
28-13	
28-14	

28-15	
28-16	
28-17	
28-18	
28-19	










a compound of the formula , wherein Rx has one of the meanings given in the following table:


Compound	Rx
29-1	
29-2	
29-3	






a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
31-2	 ;




a compound of the formula  , wherein Rx has one of the meanings given in the following table:

Compound	Rx
32-1	 ;
32-2	 ;




a compound of the formula , wherein Ry has one of the meanings given in the following table:

Compound	Ry
34-1	
34-3	
34-4	
34-6	




a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
35-1	 ;


or a pharmaceutically acceptable salt thereof.

47. (Previously Presented) The compound of claim 36, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or N²-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

48. (Previously Presented) A process for the production of a compound of formula I according to claim 36, comprising reacting a compound of formula II



wherein R⁰, R¹, R², R³, R⁴, R⁵, and R⁶ are as defined in claim 36, and Y is a leaving group, with a compound of formula III



wherein A, R⁷, R⁸, R⁹ and R¹⁰ are as defined in claim 36; and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 36, into another compound of formula I as defined in claim 36;

and recovering the resulting compound of formula I in free form or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

49. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 36, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

50. (Previously Presented) A combination comprising a therapeutically effective amount of a compound according to claim 36 and one or more known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

51. (Previously Presented) A method for the treatment of breast tumors in a subject in need thereof which comprises administering an effective amount of a compound according to claim 36 or a pharmaceutical composition comprising same.

52. (Previously Presented) The method of claim 51, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or N²-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.